Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Werewolf Therapeutics (NASDAQ:HOWLGet Rating) from a sell rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass. “

Werewolf Therapeutics stock opened at $4.15 on Tuesday. Werewolf Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $23.99. The firm has a 50 day moving average price of $5.38 and a 200 day moving average price of $10.44. The company has a market capitalization of $114.76 million and a PE ratio of -0.05.

Werewolf Therapeutics (NASDAQ:HOWLGet Rating) last issued its quarterly earnings results on Thursday, March 24th. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.13). As a group, research analysts predict that Werewolf Therapeutics will post -2.43 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Morgan Stanley lifted its position in shares of Werewolf Therapeutics by 467.0% during the 3rd quarter. Morgan Stanley now owns 1,514 shares of the company’s stock worth $26,000 after purchasing an additional 1,247 shares during the last quarter. UBS Group AG lifted its position in shares of Werewolf Therapeutics by 63.9% during the 3rd quarter. UBS Group AG now owns 1,639 shares of the company’s stock worth $28,000 after purchasing an additional 639 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Werewolf Therapeutics by 238.6% during the 4th quarter. Legal & General Group Plc now owns 2,492 shares of the company’s stock worth $30,000 after purchasing an additional 1,756 shares during the last quarter. Citigroup Inc. lifted its position in shares of Werewolf Therapeutics by 813.5% during the 4th quarter. Citigroup Inc. now owns 7,920 shares of the company’s stock worth $94,000 after purchasing an additional 7,053 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY purchased a new stake in shares of Werewolf Therapeutics during the 4th quarter worth $101,000. 69.05% of the stock is owned by institutional investors.

About Werewolf Therapeutics (Get Rating)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

See Also

Get a free copy of the Zacks research report on Werewolf Therapeutics (HOWL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Werewolf Therapeutics (NASDAQ:HOWL)

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.